Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Accumulated Expenses (2016 - 2025)

Editas Medicine (EDIT) has disclosed Accumulated Expenses for 11 consecutive years, with $47.5 million as the latest value for Q3 2025.

  • Quarterly Accumulated Expenses rose 65.09% to $47.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $47.5 million through Sep 2025, up 65.09% year-over-year, with the annual reading at $45.9 million for FY2024, 32.68% up from the prior year.
  • Accumulated Expenses for Q3 2025 was $47.5 million at Editas Medicine, down from $48.1 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $48.1 million in Q2 2025, with the low at $4.4 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $24.8 million, with a median of $28.8 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses plummeted 52.53% in 2021, then surged 465.49% in 2023.
  • Over 5 years, Accumulated Expenses stood at $10.2 million in 2021, then skyrocketed by 208.06% to $31.3 million in 2022, then increased by 10.44% to $34.6 million in 2023, then soared by 32.68% to $45.9 million in 2024, then increased by 3.63% to $47.5 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $47.5 million, $48.1 million, and $47.5 million for Q3 2025, Q2 2025, and Q1 2025 respectively.